A
argenx
Platform for antibody lead choice that supports the discovery of human antibody therapeutics
At a glance
- Status
- Listed
- Listing
- IPO 2014
Knowledge graph
Market map
Rare Disease Therapeutics & Technologies Landscape
Market map
TechBio x Drug discovery (Europe & Israel)
Market map
Digital therapeutics
Unicorn list
Biotech & Life Sciences unicorns
Unicorn list
Unicorns in Belgium
Analysis
European health companies to watch in 2026
Oct 7, 2026
Analysis
German diaspora have built $342.5B of unicorns abroad
Sep 15, 2026
Analysis
The most valuable companies in the German Diaspora Index
Sep 15, 2026
Open roles
argenx in the Ghent ecosystem
The argenx office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
- MPMVM Life Science Partners
- FPForbion Capital Partners
- OCOmnes Capital
- KBKBC
- TCThuja Capital
BioGeneration Ventures- EFErasmus MC Biomedical Fund
Series B and later4 investors entered at this stage
OrbiMed- ESEQT Life Sciences
- PMPMV
- SPSeventure Partners
Source: Dealroom Talent Intelligence.
Patents
81 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where argenx was the backer or acquirer, 2019–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across argenx's capital deployment.
Where the deals concentrate by sector, stage, and decade.
argenx's portfolio, mapped.
See argenx on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
argenx expands use of Cradle's AI protein-design platform
argenx bets up to $1.15B to buy peptide specialist Unnatural Products
argenx stops Phase 3 UNITY trial of efgartigimod in Sjögren's disease